Singapore markets closed

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.65+0.46 (+4.51%)
At close: 04:00PM EDT
10.65 0.00 (0.00%)
After hours: 04:00PM EDT

Repare Therapeutics Inc.

7210 Frederick-Banting
Suite 100
Montreal, QC H4S 2A1

Full-time employees180

Key executives

NameTitlePayExercisedYear born
Mr. Lloyd Mitchell SegalPres, CEO & Director913.37k148.07k1964
Mr. Steve ForteExec. VP & CFO608.52kN/A1979
Dr. Michael Zinda Ph.D.Exec. VP & Chief Scientific Officer655.28k1.07M1971
Dr. Maria Koehler M.D., Ph.D.Exec. VP & Chief Medical Officer669.83k892.97k1958
Dr. Daniel Durocher Ph.D.Co-FounderN/AN/AN/A
Dr. Frank Sicheri Ph.D.Co-FounderN/AN/AN/A
Dr. Agnel Sfeir Ph.D.Co-FounderN/AN/AN/A
Mr. Cameron BlackExec. VP of DiscoveryN/AN/AN/A
Dr. Kim A. Seth Ph.D.Exec. VP & Chief Bus. OfficerN/AN/AN/A
Mr. Philip HermanExec. VP, Chief Commercial & Portfolio Devel. OfficerN/AN/A1980
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Corporate governance

Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.